LIGAND PHARMACEUTICALS INCORPORATED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 82.88 USD | +3.13% |
|
+14.91% | +16.36% |
| May. 08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
| May. 08 | Ligand Pharmaceuticals Shares Rise After Q1 Adjusted Earnings, Revenue Beat Views | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 138M | Sales 2025 * | 158M | Capitalization | 1.44B |
|---|---|---|---|---|---|
| Net income 2024 * | 39M | Net income 2025 * | 51M | EV / Sales 2024 * | 10.5 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 9.15 x |
| P/E ratio 2024 * |
36.7
x | P/E ratio 2025 * |
28.1
x | Employees | 58 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.56% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ligand Pharmaceuticals Incorporated
More recommendations
More press releases
| 1 day | +9.75% | ||
| 1 week | +12.52% | ||
| Current month | +14.98% | ||
| 1 month | +0.95% | ||
| 3 months | +6.56% | ||
| 6 months | +53.86% | ||
| Current year | +12.52% |
1 week
72.57
81.43
1 month
67.7281.73
Current year
67.5394.57
1 year
49.2494.57
3 years
49.24169.98
5 years
49.24219.75
10 years
41.99278.62
| Managers | Title | Age | Since |
|---|---|---|---|
Todd Davis
CEO | Chief Executive Officer | 63 | 07-02-28 |
Octavio Espinoza
DFI | Director of Finance/CFO | 53 | 22-10-31 |
| President | 49 | 15-08-05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Kozarich
CHM | Chairman | 74 | 03-02-28 |
John LaMattina
BRD | Director/Board Member | 74 | 11-01-31 |
Stephen Sabba
BRD | Director/Board Member | 64 | 08-08-03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.24% | 0 M€ | -3.26% | - | |
| 0.14% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 83.1 | +3.42% | 285 350 |
| 24-05-08 | 80.36 | +9.75% | 286,959 |
| 24-05-07 | 73.22 | +0.54% | 162,711 |
| 24-05-06 | 72.83 | -1.45% | 114,789 |
| 24-05-03 | 73.9 | +2.18% | 141,782 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotes
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
80.36
USD
Average target price
116.8
USD
Spread / Average Target
+45.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.52% | 1.44B | |
| +32.95% | 698B | |
| +26.51% | 568B | |
| -4.97% | 358B | |
| +18.83% | 328B | |
| +3.54% | 283B | |
| +15.70% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +6.70% | 165B |
- Stock Market
- Equities
- LGND Stock